EUVIMEDEUVIMED entdecken
Crossref

Trop2-Targeted [ 18 F]AlF-RESCA-RT4 ImmunoPET/CT in Guiding Clinical Surgeries of Thyroid Cancers: A Proof-of-Concept Study

Xinlu Yin iD, Wenzhi Jia, Le Xu, Wenjie Zheng, Yiqing Gao, Linglin Tang, You Zhang, Qianyun Wu, Dongsheng Xu, Shuxian An iD, Weijun Wei iD, Jianjun Liu und 3 weitere

Molecular Pharmaceutics · 02.03.2026 · 23 (3) · 1696-1704

DOI: 10.1021/acs.molpharmaceut.5c01423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 23.01.2026. Verfasst von Xinlu Yin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Renji Hospital of Shanghai Jiao Tong University, School of Medicine, Pujian Road 160, Shanghai 200001, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Cell Adhesion Molecules, Antigens, Neoplasm, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Bethune Charitable Foundation, National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current imaging techniques (ultrasonography, CT) have limited sensitivity for detecting occult lymph node metastases in thyroid cancers. This first-in-human study assesses Trop2-targeted immunoPET/CT for preoperative differentiation of benign and malignant thyroid nodules and for identifying lymph node metastases to aid surgical planning. Sixteen patients with thyroid cancer underwent preoperative Trop2-targeted immunoPET/CT imaging. Tracer uptake (SUVmax) in tumors and lymph nodes was measured, pathology was confirmed through histopathology, and Trop2 expression was validated by immunohistochemistry. Malignant thyroid cancers had higher Trop2 tracer uptake than benign (38.46 ± 8.04 vs 8.97 ± 4.80, P = 0.046), and PTC had a 6.2-fold increase over adjacent normal tissue (46.65 ± 7.54 vs 7.53 ± 1.71, P = 0.007). The uptake value of the Trop2 tracer was strongly correlated to PTC tumor size (Spearman correlation coefficient ρ = 0.81, R2 = 0.66). Trop2 immunoPET/CT effectively differentiates metastatic lymph nodes (LN (+): 25.15 ± 5.16 vs LN (-): 3.34 ± 1.27, P = 0.00017), with an AUC of 0.89 (95% CI: 0.78-1.00). Diagnosis of lymph node metastasis achieved an accuracy of 91.3%. Both metastatic lymph nodes and PTC show high Trop2 tracer uptake, but there was no statistically significant difference between them (46.65 ± 7.54 vs 25.15 ± 5.16, P = 0.252). Trop2 tumor proportion score and SUVmax were strongly correlated (Spearman correlation coefficient ρ = 0.88; R2 = 0.64). Consequently, the following conclusions can be drawn: Trop2 immunoPET/CT offers superior diagnostic accuracy for PTC and metastatic lymph nodes, enhances surgical planning, and may revolutionize the clinical management of PTCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsCell Adhesion MoleculesAntigens, NeoplasmPositron Emission Tomography Computed TomographyHumansFemaleLymphatic MetastasisMiddle AgedMaleAdultAgedLymph NodesRadiopharmaceuticals

Stichwörter der Autor:innen

CTTrop2immunoPETlymph node metastasismolecular imagingthyroid cancer

Substanzen

TACSTD2 protein, humanCell Adhesion MoleculesAntigens, NeoplasmRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Head and Neck Surgery, Renji Hospital of Shanghai Jiao Tong University, School of Medicine, Pujian Road 160, Shanghai 200001, China.
  • Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Pujian Road 160, Shanghai 200127, China.
  • Department of General Surgery, Shanghai Jiading District Central Hospital, Chengbei Road 1, Shanghai 201800, China.

ORCID-Profile: Xinlu Yin, Shuxian An, Weijun Wei

Förderung

  • Bethune Charitable Foundation
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shanghai Jiading District Health Commission Scientific Research Project
  • Physician-Scientist Development Award from Shanghai Immune Therapy Institute

Zitieren

APA

Yin, X., Jia, W., Xu, L., Zheng, W., Gao, Y., Tang, L., Zhang, Y., Wu, Q., Xu, D., An, S., Wei, W., Liu, J., Zhou, Q., Feng, J., & Chen, J. (2026). Trop2-Targeted [ 18 F]AlF-RESCA-RT4 ImmunoPET/CT in Guiding Clinical Surgeries of Thyroid Cancers: A Proof-of-Concept Study. Molecular Pharmaceutics, 23(3), 1696-1704. https://doi.org/10.1021/acs.molpharmaceut.5c01423

Vancouver

Yin X, Jia W, Xu L, Zheng W, Gao Y, Tang L, et al. Trop2-Targeted [ 18 F]AlF-RESCA-RT4 ImmunoPET/CT in Guiding Clinical Surgeries of Thyroid Cancers: A Proof-of-Concept Study. Molecular Pharmaceutics. 2026;23(3):1696-1704. doi:10.1021/acs.molpharmaceut.5c01423

BibTeX
@article{Yin2026,
  author = {Yin, Xinlu and Jia, Wenzhi and Xu, Le and Zheng, Wenjie and Gao, Yiqing and Tang, Linglin and Zhang, You and Wu, Qianyun and Xu, Dongsheng and An, Shuxian and Wei, Weijun and Liu, Jianjun and Zhou, Qinyi and Feng, Jialin and Chen, Jun},
  title = {Trop2-Targeted [ 18 F]AlF-RESCA-RT4 ImmunoPET/CT in Guiding Clinical Surgeries of Thyroid Cancers: A Proof-of-Concept Study},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {3},
  pages = {1696--1704},
  doi = {10.1021/acs.molpharmaceut.5c01423}
}
Kostenlos starten →